Conference: AMWA NorCal Pacific Coast Conference
Date: May 15 - 16, 2026
Location: North Carolina Biotech Center. Durham, NC
Hear insights from Certara’s experts:
Speaker: Brenda Taylor, MS
The time being allowed from receipt of last study data to submission of a marketing or new drug application continues to shrink. The demands of planning realistic timelines, maintaining messaging, and writing documents in parallel continues to increase. Efficiency can be obtained through extensive planning, prototyping, and by agreeing on presentation and messaging in the last CSR before draft 1 of the summaries and overviews. Methods for enabling this simultaneous writing of reports, summaries, and overviews will be discussed, including designating the one source of truth. I will also discuss the pros and cons of lockdown meetings and top-down support for the review and approval process.

Brenda Taylor
Director of Global SubmissionsBrenda Taylor is a Director of Global Submissions at Certara. She has over 20 years of experience in the biotechnology and pharmaceutical industry. She has led regulatory strategy and submission management activities to support pharmaceutical development and manufacturing, with an emphasis on Initial New Drug (IND) applications and marketing applications. Brenda’s research background in microbiology and immunology includes design and performance of nonclinical studies. Her therapeutic areas of expertise include oncology, cardiovascular, and anti-infective agents, spanning both small-molecule drugs and biologics.
Join Certara’s team of expert regulatory writers.
We’re seeking innovators ready to shape the future of regulatory writing. Contact us to discuss Principal, Associate, or Writer II roles and make your impact.
You May Also Like


